Roxadustat is an emerging and promising therapeutic approach against anemia in CKD patients, which differs from those of conventional ESAs. Roxadustat corrects anemia of CKD patients through multiple pathways, beyond elevating EPO levels within physiological range, and also by handling iron metabolism (particularly decreasing the hepcidin levels). Furthermore, the Hb response of roxadustat is independent of the inflammatory microenvironment.
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor used to treat anemia in chronic kidney disease. Its core mechanism involves stabilizing HIF-1α to enhance endogenous erythropoietin production. Molecular formula: C26H24N4O5; CAS No.: 1079889-92-3.
Contraindicated in severe hepatic impairment; monitor blood pressure closely due to hypertension risks. Store under inert atmosphere at 2–8°C to maintain chemical stability and prevent degradation.